Clinical trials: Lung Cancer, Small Cell
Non Small Cell Lung Cancer
A Study of Pemetrexed and Cisplatin, in Non Small Cell Lung Cancer
This trial investigates pemetrexed and cisplatin followed by pemetrexed and cisplatin in combination with radiotherapy in participants with locally advanced, non-small cell lung cancer (NSCLC).
- Trial name
- NCT01000480
- Testing
- Pemetrexed, Cisplatin, Thoracic Radiotherapy
- Where
- 21 sites in France, Germany and 2 more
- Volunteers
- 90 people
- Sponsor
- Eli Lilly and Company
Non-small Cell Lung Cancer (NSCLC)
Individualized Lung Tumor Stereotactic Ablative Radiotherapy (iSABR)
A research study of a procedure to treating lung cancer with focused radiation called Stereotactic Ablative Radiotherapy (SABR).
- Trial name
- NCT01463423
- Testing
- iSABR, 25 Gray in 1 fraction for small peripheral tumors, iSABR, 50 Gray in 4 fractions for medium peripheral tumors, iSABR, 54 Gray in 3 fractions for large peripheral tumors
- Where
- 4 sites in United States, Canada and 1 more
- Volunteers
- 256 people
- Sponsor
- Stanford University
Non-squamous Non-small Cell Lung Cancer
Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Adults Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers
The purpose of this study is to evaluate the safety and efficacy of veliparib plus carboplatin and paclitaxel versus the Investigator's choice of standard chemotherapy in adults with metastatic or advanced non-squamous non-small…
- Trial name
- NCT02264990
- Testing
- Paclitaxel, Carboplatin, Cisplatin
- Where
- 140 sites in United States, Argentina and 18 more
- Volunteers
- 595 people
- Sponsor
- AbbVie
Small Cell Lung Cancer
Study of Abraxane and Carboplatin to Treat Small Cell Lung Cancer
This is a phase II trial of abraxane and carboplatin in extensive stage small cell lung cancer to examine overall response rate, time to progressive disease, survival time, and assessment of toxicity profile for Carboplatin and…
- Trial name
- NRR (NCT00454324)
- Testing
- Carboplatin, Abraxane
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Non-small Cell Lung Cancer
National Comprehensive Cancer Network (NCCN) Decision Support Tool for Patients With NSCLC
This study involves the evaluation of a decision support tool, based on the patient version of the NCCN guidelines, for the non-small cell lung cancer patient population.
- Trial name
- NCT03982459
- Testing
- Decision support tool
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- University of California, San Francisco
Lung Cancer, Tobacco Use Disorder
Feasibility of Delivering a Quitline Based Smoking Cessation Intervention in Cancer Patients
RATIONALE: Continued smoking after a cancer diagnosis has important health consequences beyond the risks associated with smoking in the general population.
- Conditions
- Lung Cancer, Tobacco Use Disorder, Breast Cancer, Colorectal Cancer
- Trial name
- NCT01434342
- Testing
- Nicotine Replacement Patch
- Where
- United States
- Volunteers
- 146 people
- Sponsor
- Wake Forest University Health Sciences
Non Small Cell Lung Cancer
Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy
To determine if ZD6474 a new investigational drug, is effective in treating Non Small Lung Cancer and if so, how it compares with another type of anti cancer therapy chemotherapy, Erlotinib
- Trial name
- NCT00364351
- Testing
- Vandetanib, Erlotinib
- Where
- 153 sites in United States, Argentina and 20 more
- Volunteers
- 1,574 people
- Sponsor
- Genzyme, a Sanofi Company
Non-Small Cell Lung Cancer
A Global Study to Assess the Effects of MEDI4736 Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer
A Global Study to Assess the Effects of MEDI4736 following concurrent chemoradiation in Patients with Stage III Unresectable Non-Small Cell Lung Cancer.
- Trial name
- PACIFIC (NCT02125461)
- Testing
- MEDI4736
- Where
- 236 sites in United States, Australia and 24 more
- Volunteers
- 713 people
- Sponsor
- AstraZeneca
Neoplasms
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 3
This study is a sub-study of the master protocol 205801 (NCT03739710). This sub study will assess safety and pharmacokinetics and pharmacodynamics (PK/PD) of novel regimens (Dostarlimab plus belrestotug , and Dostarlimab plus…
- Trial name
- NCT06926673
- Testing
- Dostarlimab, Belrestotug., Nelistotug
- Where
- 15 sites in United States, Canada and 4 more
- Volunteers
- 62 people
- Sponsor
- GlaxoSmithKline
Non-Small-Cell Lung Cancer
A Study for Non-Smoker Patients With Nonsquamous Non-Small Cell Lung Cancer
The purpose of this study is to compare the combination of erlotinib and pemetrexed versus either pemetrexed alone and erlotinib alone, in terms of progression-free survival (time until the objective worsening of the disease) in…
- Trial name
- NCT00550173
- Testing
- pemetrexed, erlotinib
- Where
- 29 sites in Brazil, China and 5 more
- Volunteers
- 247 people
- Sponsor
- Eli Lilly and Company
Non-Small Cell Lung Cancer
Pemetrexed and Best Supportive Care Versus Placebo and Best Supportive Care in Non-Small Cell Lung Cancer (NSCLC)
This study is a randomized Phase 3, double-blind study of maintenance pemetrexed plus best supportive care versus placebo plus best supportive care in NSCLC.
- Trial name
- NCT00102804
- Testing
- Pemetrexed, Best Supportive Care
- Where
- 73 sites in United States, Australia and 18 more
- Volunteers
- 663 people
- Sponsor
- Eli Lilly and Company
Carcinoma, Non Small Cell Lung
Docetaxel +/- Suramin in 2nd Line Advanced Non-Small Cell Lung Cancer
The overall purpose of the study is to determine whether or not the inclusion of suramin to standard treatment with docetaxel improves progression-free survival for patients with advanced non-small cell lung cancer in the second…
- Trial name
- NCT01671332
- Testing
- Docetaxel, Suramin
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- University of Wisconsin, Madison
Lung Cancer
BELIEF (Bevacizumab and ErLotinib In EGFR Mut+ NSCLC)
Rationale: Advanced non-small-cell lung cancer (NSCLC) patients harbouring epidermal growth factor receptor (EGFR) mutations (del19 or L858R) show an impressive progression-free survival between 9 and 14 months when treated with…
- Trial name
- BELIEF (NCT01562028)
- Testing
- Erlotinib, Bevacizumab
- Where
- 48 sites in France, Germany and 6 more
- Volunteers
- 109 people
- Sponsor
- ETOP IBCSG Partners Foundation
Carcinoma, Non-Small-Cell Lung
Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 (Afatinib) Plus Sirolimus (Rapamune®) in Patients With Non-small Cell Lung Cancer Harbouring an EGFR Mutation and/or Disease Progression Following Prior Erlotinib or Gefitinib
The primary objective of this trial is to identify the Maximum Tolerated Dose of BIBW 2992 therapy when given continuously in combination with Sirolimus.
- Trial name
- NCT00993499
- Testing
- BIBW 2992, Sirolimus (rapamycin)
- Where
- 8 sites in Spain
- Volunteers
- 44 people
- Sponsor
- Boehringer Ingelheim
Multiple Myeloma, Diffuse Large B-Cell Lymphoma
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
The main purpose of this first human study with CC-223 is to assess the safety and action of a new class of experimental drug (dual mTOR inhibitors) in patients with advanced tumors unresponsive to standard therapies and to…
- Conditions
- Multiple Myeloma, Diffuse Large B-Cell Lymphoma, Glioblastoma Multiforme, Hepatocellular Carcinoma
- Trial name
- NCT01177397
- Testing
- CC-223
- Where
- 16 sites in United States, France and 2 more
- Volunteers
- 226 people
- Sponsor
- Celgene
Non-small Cell Lung Cancer
Hypofractionated Image-Guided Radiation Therapy (IGRT) in Patients With Stage II-III Non-Small Cell Lung Cancer
The study is designed to determine whether an accelerated course of hypofractionated radiation therapy with daily image guidance and motion assessment/control will allow more effective treatment of poor performance status…
- Trial name
- NCT01459497
- Testing
- Radiation Therapy, Conventional radiation
- Where
- 7 sites in United States
- Volunteers
- 103 people
- Sponsor
- University of Texas Southwestern Medical Center
Advanced Malignancies, Metastatic Cancer
Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies
The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies in subjects with advanced or metastatic malignancies.
- Trial name
- NCT03126110
- Testing
- INCAGN01876, Nivolumab, Ipilimumab
- Where
- 38 sites in United States, Australia and 2 more
- Volunteers
- 145 people
- Sponsor
- Incyte Biosciences International Sàrl
Non-Small Cell Lung Cancer
Pembrolizumab + Imprime PGG for Metastatic Non-small Cell Lung Cancer After Progression on First-Line Therapy: Big Ten Cancer Research Consortium BTCRC-LUN15-017
This is an open label, multi-institutional, single arm study with a dose escalation phase Ib cohort, followed by a phase II cohort of pembrolizumab and Imprime PGG. No randomization or blinding is involved.
- Trial name
- NCT03003468
- Testing
- Imprime PGG, MK-3475
- Where
- 5 sites in United States
- Volunteers
- 35 people
- Sponsor
- Lawrence Feldman, MD
Non-Small-Cell Lung Carcinoma
ZD6474 (ZACTIMA™) Phase III Study in EGFR Failures
This study is being carried out to assess if adding ZD6474 to best supportive care (BSC) is more effective than best supportive care alone, for the treatment of patients with non-small cell lung cancer, whose disease has recurred…
- Trial name
- NCT00404924
- Testing
- ZD6474 (vandetanib), Best Supportive Care
- Where
- 102 sites in United States, Argentina and 20 more
- Volunteers
- 1,140 people
- Sponsor
- Genzyme, a Sanofi Company
Non Small Cell Lung Carcinoma
Randomized Phase II Study of AZD6244 (Mitogen-activated Protein Kinase Inhibitor) MEK-Inhibitor With Erlotinib in KRAS Wild Type Advanced Non-Small Cell Lung Cancer (NSCLC) and a Randomized Phase II Study of AZD6244 With Erlotinib in Mutant KRAS Adva...
Background: AZD6244 (ARRY-142886) is an investigational anticancer drug that is designed to block a critical component (MEK (methyl ethyl ketone)) of a pathway (MAP (mitogen-activated protein) kinase pathway) that causes some…
- Trial name
- NCT01229150
- Testing
- AZD6244, Erlotinib, AZD6244 + Erlotinib
- Where
- 5 sites in United States
- Volunteers
- 89 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.